CalciMedica Extends Debt Maturity, Amends Warrants, and Increases Conversion Option to Address Liquidity

summarizeSummary

CalciMedica amended its loan terms, extending debt maturity and interest-only periods, but significantly increased potential dilution through new and repriced warrants and an expanded debt-to-equity conversion option, critical for a company facing going concern doubts.

check_boxKey Events

• Loan Terms Extended

  The interest-only period for the $10 million outstanding principal was extended by one year to September 30, 2027, and the maturity date was extended by one year to September 1, 2029.

• Increased Debt-to-Equity Conversion Option

  The lender's right to convert loan principal into common stock or pre-funded warrants was increased from $1 million to $3 million, at a conversion price of $1.00 per share.

• Existing Warrant Exercise Price Reduced

  An existing warrant for 641,163 shares, issued in February 2025, had its exercise price reduced from $2.32 to $1.00 per share.

• New Warrant Issued

  The company issued a new warrant to the lender for 1,000,000 shares of common stock, with an exercise price of $1.00 per share, exercisable until June 23, 2031.

auto_awesomeAnalysis

CalciMedica, a company that recently disclosed "substantial doubt about its ability to continue as a going concern," has secured a critical amendment to its loan agreement. This amendment extends the interest-only period and maturity date by one year, providing crucial financial runway. However, this comes with significant potential dilution. The lender's right to convert up to $3 million of principal into common stock or pre-funded warrants, combined with a new warrant for 1 million shares and a reduced exercise price for an existing warrant (from $2.32 to $1.00), represents a substantial increase in potential shares. While the exercise price of $1.00 for these securities is currently above the market price of $0.80, indicating the lender's belief in future appreciation, the sheer volume of potential new shares (up to 4.64 million from warrants and conversion) is highly dilutive relative to the company's small market capitalization. The company also gained a "Put Option" to force conversion under certain conditions, giving it some control over the timing of this dilution. This deal is a necessary step to address immediate liquidity concerns and extend the company's operational timeline.